Here is My Question:
I am a SPMS patient and have had MS for 40 years. I am interested in starting Mayzent which is a new medicine for the SPMS patients. I would like to find out how patients have started on Matzent, How they are doing on the Mayzent...any reactions or anything else? Thank You.
Mayzent (generic name Siponimod) is the newest SIP1 receptor modulator. The oldest, and currently the only other available, SIP1 receptor modulator is Gilenya (generic name Fingolimod). Mayzent is called a selective SIP1 receptor modulator because it only binds to the type 1 and type 5 receptors, whereas Gilenya binds to all SIP1 receptors. For practical purposes this has little effect on the side effect profile of these drugs.
The most common side effects are headache, elevated blood pressure and elevated liver enzymes. Less common or rare side effects include macular edema (usually beginning in the first 4 months of treatment), shortness of breath, cardiac arrhythmias (abnormal heart beat), various infections including shingles and a condition called posterior reversible encephalopathy syndrome. Physicians monitor regularly for these conditions, all of which are reversible with prompt identification and treatment
I am not aware of any other unexpected problems emerging since the drug was approved and released by the FDA.
Revere (Rip) Kinkel MD
Professor of Clinical Neurosciences
Director of the Multiple Sclerosis Program
Clinical Neurosciences Director
University of California San Diego
PLEASE NOTE: This information/opinions on this site should be used as an information source only. This information does not create any patient-HCP relationship, and should not be used as a substitute for professional diagnosis and treatment. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition.